摘要
中性粒细胞胞外陷阱(NETs)是一种网状结构,由激活的中性粒细胞释放。近代研究显示,中性粒细胞胞外陷阱在促进自身免疫和疾病中组织损伤等方面发挥积极作用,如风湿性关节炎和全身性红斑狼疮等。本课题研究目的在于探究雷公藤红色、三萜化合物能否抑制中性粒细胞的形成,包括与风湿性关节炎和全身性红斑狼疮。我们发现雷公藤红色能完全抑制中性粒细胞氧化迸发及中性粒细胞的形成,被肿瘤坏死因子(半数抑制浓度为0.34um)和卵清蛋白诱导产生:反卵清蛋白免疫复合物(半抑制浓度为1.53um)。南蛇藤醇能完全抑制中性粒细胞的氧化迸发和由免疫球蛋白G(IgG)诱导产生的中性粒细胞,而IgG可净化风湿性关节炎和全身性红斑狼疮病人的血清。经过对机制进一步研究,我们发现雷公藤红色可抑制脾酪氨酸激酶的活性和促分裂原活化蛋白激酶、胞外信号控制激酶、NFκB抑制剂IκBα的共同磷酸化以及组蛋白的瓜氨酸化。我们的数据显示,雷公藤红色有效地抑制了中性粒细胞的氧化迸发和由不同炎症刺激物诱发中性粒细胞的形成,可能通过抑制SYK-MEK-ERK-NFκB信号级联放大。结果表明,雷公藤红色可能在炎症性和自身免疫性疾病治疗方面发挥很大潜力。
关键词: 关节炎,雷公藤红色,炎症,红斑狼疮,中性粒细胞胞外陷阱
Current Molecular Medicine
Title:Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Volume: 15 Issue: 4
Author(s): Y. Yu, C.D. Koehn, Y. Yue, S. Li, G.M. Thiele, M.P. Hearth-Holmes, T.R. Mikuls, J.R. O’Dell, L.W. Klassen, Z. Zhang and K. Su
Affiliation:
关键词: 关节炎,雷公藤红色,炎症,红斑狼疮,中性粒细胞胞外陷阱
摘要: Neutrophil extracellular traps (NETs) are web-like structures released by activated neutrophils. Recent studies suggest that NETs play an active role in driving autoimmunity and tissue injury in diseases including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The purpose of this study was to investigate if celastrol, a triterpenoid compound, can inhibit NET formation induced by inflammatory stimuli associated with RA and SLE. We found that celastrol can completely inhibit neutrophil oxidative burst and NET formation induced by tumor necrosis factor alpha (TNFα) with an IC50 of 0.34 µM and by ovalbumin:anti-ovalbumin immune complexes (Ova IC) with an IC50 of 1.53 µM. Celastrol also completely inhibited neutrophil oxidative burst and NET formation induced by immunoglobulin G (IgG) purified from RA and SLE patient sera. Further investigating into the mechanisms, we found that celastrol treatment downregulated the activation of spleen tyrosine kinase (SYK) and the concomitant phosphorylation of mitogen-activated protein kinase kinase (MAPKK/MEK), extracellular-signal-regulated kinase (ERK), and NFκB inhibitor alpha (IκBα), as well as citrullination of histones. Our data reveals that celastrol potently inhibits neutrophil oxidative burst and NET formation induced by different inflammatory stimuli, possibly through downregulating the SYK-MEK-ERK-NFκB signaling cascade. These results suggest that celastrol may have therapeutic potentials for the treatment of inflammatory and autoimmune diseases involving neutrophils and NETs.
Export Options
About this article
Cite this article as:
Y. Yu, C.D. Koehn, Y. Yue, S. Li, G.M. Thiele, M.P. Hearth-Holmes, T.R. Mikuls, J.R. O’Dell, L.W. Klassen, Z. Zhang and K. Su , Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation, Current Molecular Medicine 2015; 15 (4) . https://dx.doi.org/10.2174/1566524015666150505160743
DOI https://dx.doi.org/10.2174/1566524015666150505160743 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabolism of HDL and its Regulation
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design Cytokines: From Gut Inflammation to Colorectal Cancer
Current Drug Targets Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Capillaroscopic Findings in Primary Fibromyalgia
Current Rheumatology Reviews The Insulin-like Growth Factor-1 Axis and its Potential as a Therapeutic Target in Central Nervous System (CNS) Disorders
Central Nervous System Agents in Medicinal Chemistry Macronutrient Intake and Distribution in the Etiology, Prevention and Treatment of Osteosarcopenic Obesity
Current Aging Science Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Stimuli-responsive Drug Delivery Systems as an Emerging Platform for Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Pleural Involvement in Systemic Disorders
Current Drug Targets - Inflammation & Allergy A Role of the 9-Aminoacridines and their Conjugates in a Life Science
Current Protein & Peptide Science Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Pyrazoles as Promising Scaffold for the Synthesis of Anti-Inflammatory and/or Antimicrobial Agent: A Review
Mini-Reviews in Medicinal Chemistry Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry